Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03869333 · ClinicalTrials.gov registry record · Phase 1
Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]
A Phase 1 study of Diarrhea, sponsored by PATH.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT03869333 is a Phase 1 study of Diarrhea that has completed, run by PATH. The registered enrollment target is 58 participants, below the 155-participant average among 24 other Diarrhea trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03869333, a Phase 1 study of Diarrhea, has completed, sponsored by PATH.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to evaluate the safety of a Shigella flexneri 2a detoxified artificial invasin complex (Invaplex\[AR-Detox\]) vaccine candidate administered by intramuscular immunization.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Invaplex[AR-DETOX]
Study Locations (1)
Maryland
- Walter Reed Army Institute of Research Clinical Trials Center (WRAIR CTC) - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2019-03-18 |
| Est. Completion | 2020-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03869333
The ClinicalTrials.gov registry entry for NCT03869333 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 155-participant average among 24 other Diarrhea trials with a reported enrollment target (63% lower). The listed sponsor is PATH, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diarrhea appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03869333 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03869333 about?
NCT03869333 is a clinical study titled "Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]". The main purpose of this study is to evaluate the safety of a Shigella flexneri 2a detoxified artificial invasin complex (Invaplex\[AR-Detox\]) vaccine candidate administered by intramuscular immunization.
What is the current status of trial NCT03869333?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2019-03-18. Estimated completion is 2020-06-12.
What conditions does trial NCT03869333 study?
This clinical trial studies the following conditions: Diarrhea.
What interventions are being tested in trial NCT03869333?
The interventions under investigation include: Placebo (OTHER), Invaplex[AR-DETOX] (BIOLOGICAL).
Who is sponsoring clinical trial NCT03869333?
This trial is sponsored by PATH, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03869333 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diarrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
RECRUITING · Phase 1
-
First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults
RECRUITING · Phase 1
-
A Study of SER-155 to Treat Diarrhea in People on Immunotherapy
RECRUITING · Phase 1
-
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
COMPLETED · Phase 1
-
Invaplex 50 Vaccine Dose-Ranging
COMPLETED · Phase 1
-
GI Alpha-Gal Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.